Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841101 | 0.95 | MAPK14 (0.40) | MAPK14MAPK11DGAT2CNR1TRPA1 | |
| SCHEMBL4841381 | 0.91 | MAPK14 (0.40) | MAPK14MAPK11DGAT2CNR1TRPA1 | |
| SCHEMBL4845291 | 0.91 | MAPK14 (0.39) | MAPK14MAPK11DGAT2CNR1TRPA1 | |
| SCHEMBL4832594 | 0.86 | MAPK14 (0.42) | MAPK14MAPK11TRPA1METAXL | |
| SCHEMBL4839439 | 0.85 | MAPK14 (0.46) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4013149 | 0.85 | MAPK14 (0.40) | MAPK14MAPK11CNR1TRPA1MET | |
| SCHEMBL14018785 | 0.84 | MAPK14 (0.45) | MAPK14MAPK11METAXLTYRO3 | |
| SCHEMBL4840856 | 0.84 | MAPK14 (0.45) | MAPK14MAPK11METAXLTYRO3 | |
| SCHEMBL4840546 | 0.84 | MAPK14 (0.41) | MAPK14MAPK11AXLTYRO3MERTK | |
| SCHEMBL4841631 | 0.84 | MAPK14 (0.39) | MAPK14MAPK11TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | MAPK14 70/4885MAPK11 75/4885DGAT2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.